Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $21 from $23 and keeps a Buy rating on the shares. The firm remains “enthusiastic” about ENTR-601-44 and ENTR-601-45 following Entrada’s Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
- Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)
- Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
- Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment
- Entrada Therapeutics Gains UK Approval for DMD Study